Certa Therapeutics is focused on the emerging field of medical science which uses genetic information to identify which patients will best respond to a specific treatment, commonly referred to as precision medicine.
Certa Therapeutics is commencing several Phase 2 studies targeting diabetic kidney disease and focal segmental gloemrulsclerosis, where fibrosis (scarring) of the kidney leads to kidney failure and ultimately dialysis or kidney transplantation. The Company’s novel drugs block a receptor that is a key driver of this fibrosis and Certa will use genetic analysis to identify those patients that are most likely to benefit from the therapy, addressing a market worth around US$5 billion per annum.
There are currently no treatments available for kidney fibrosis and given the enormous cost of dialysis and kidney transplants to the healthcare system, finding an effective treatment for these patients remains one of the global healthcare industry’s largest unmet needs.
Certa plans to progress anti-fibrotic drug development to mid-stage clinical trials, which could provide benefit in a wide variety of disease states characterised by an inflammatory and fibrotic progression, such as DN and FSGS.